Should I buy or sell Purple Biotech stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Purple Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PPBT shares. View PPBT analyst ratings or view top-rated stocks .

What is Purple Biotech's stock price target for 2024?

3 Wall Street research analysts have issued 1 year price objectives for Purple Biotech's shares. Their PPBT share price targets range from $8.00 to $10.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,488.1% from the stock's current price. View analysts price targets for PPBT or view top-rated stocks among Wall Street analysts .

How have PPBT shares performed in 2024?

Purple Biotech's stock was trading at $0.78 at the start of the year. Since then, PPBT shares have decreased by 27.3% and is now trading at $0.5667. View the best growth stocks for 2024 here .

When is Purple Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our PPBT earnings forecast .

How were Purple Biotech's earnings last quarter?

Purple Biotech Ltd. (NASDAQ:PPBT) posted its earnings results on Tuesday, March, 5th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.15.

How do I buy shares of Purple Biotech?

Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:PPBT

Purple Biotech (PPBT) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free PPBT Stock Alerts

$0.57

-0.05 (-8.11%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.55
▼
$0.65
50-Day Range: $0.57
▼
$0.92
52-Week Range: $0.53
▼
$2.16

Volume: 184,567 shs
Average Volume: 73,080 shs
Market Capitalization: $14.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Purple Biotech alerts:

Purple Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,488.1% Upside
$9.00 Price Target
Short Interest: Healthy
0.88% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

438th out of 928 stocks

Pharmaceutical Preparations Industry

199th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Purple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Purple Biotech has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.88% of the outstanding shares of Purple Biotech have been sold short.
Short Interest Ratio / Days to Cover
Purple Biotech has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Purple Biotech has recently decreased by 0.36%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Purple Biotech does not currently pay a dividend.
Dividend Growth
Purple Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PPBT.

4.4

News and Social Media Coverage

News Sentiment
Purple Biotech has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Purple Biotech this week, compared to 0 articles on an average week.
Search Interest
4 people have searched for PPBT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
3 people have added Purple Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Purple Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.98% of the stock of Purple Biotech is held by insiders.
Percentage Held by Institutions
Only 9.64% of the stock of Purple Biotech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Purple Biotech are expected to remain at ($0.46) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Purple Biotech is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Purple Biotech is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Purple Biotech has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Purple Biotech Stock (NASDAQ:PPBT)

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

PPBT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PPBT Stock News Headlines

March 28, 2024 | finance.yahoo.com

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

March 14, 2024 | finanznachrichten.de

Purple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 14, 2024 | globenewswire.com

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

March 5, 2024 | investorplace.com

PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023

March 5, 2024 | finanznachrichten.de

Purple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

March 5, 2024 | globenewswire.com

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

March 3, 2024 | investing.com

Purple Biotech ADR (PPBT) Earnings Dates & Reports

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

February 27, 2024 | markets.businessinsider.com

Buy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN Treatment

February 27, 2024 | morningstar.com

Purple Biotech Ltd ADR

February 27, 2024 | globenewswire.com

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

February 22, 2024 | wsj.com

Purple Biotech Ltd. ADR

February 15, 2024 | morningstar.com

Purple Biotech Ltd ADR PPBT

February 13, 2024 | finance.yahoo.com

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

February 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)

February 1, 2024 | msn.com

Purple Biotech stock climbs 9% on Phase 2 study update

February 1, 2024 | finance.yahoo.com

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

December 20, 2023 | finance.yahoo.com

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

December 14, 2023 | finanznachrichten.de

Purple Biotech Ltd.: Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

December 14, 2023 | finance.yahoo.com

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

November 22, 2023 | markets.businessinsider.com

Promising Clinical Trial Results and Accelerated Enrollment Boost Purple Biotech’s Buy Rating

November 21, 2023 | finance.yahoo.com

Purple Biotech Reports Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Purple Biotech Fortifies NT219 Patent Protection

October 19, 2023 | finance.yahoo.com

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

October 17, 2023 | marketwatch.com

Purple Biotech Shares Drop 16% After Direct Offering Prices

October 17, 2023 | msn.com

Purple Biotech announces $5M direct offering to fund oncology therapeutic candidates

See More Headlines

Receive PPBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PPBT
CUSIP: N/A
CIK: 1614744
Web: www.kitovpharma.com
Phone: (723) 933-3121
Fax: 972-153-39333121
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $10.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +1,488.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,880,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -57.40%
Return on Assets: -49.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.20
Quick Ratio: 2.20

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.36 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 25,240,000
Free Float: 24,486,000
Market Cap: $14.30 million
Optionable: Optionable
Beta: 0.94

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Gil Efron CPA (Age 58)
M.A., Chief Executive Officer
Comp: $455.44k
Dr. Michael Schickler Ph.D. (Age 66)
Head of Clinical & Regulatory Affairs
Comp: $264.98k
Mr. Lior Fhima CPA (Age 47)
M.B.A., Chief Financial Officer
Mr. Ido Morpurgo B.Sc. (Age 52)
L.L.M., Vice President of Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PPBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Purple Biotech stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Purple Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PPBT shares.
View PPBT analyst ratings or view top-rated stocks.
What is Purple Biotech's stock price target for 2024?: 3 Wall Street research analysts have issued 1 year price objectives for Purple Biotech's shares. Their PPBT share price targets range from $8.00 to $10.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,488.1% from the stock's current price.
View analysts price targets for PPBT or view top-rated stocks among Wall Street analysts.
How have PPBT shares performed in 2024?: Purple Biotech's stock was trading at $0.78 at the start of the year. Since then, PPBT shares have decreased by 27.3% and is now trading at $0.5667.
View the best growth stocks for 2024 here.
When is Purple Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our PPBT earnings forecast.

How were Purple Biotech's earnings last quarter?: Purple Biotech Ltd. (NASDAQ:PPBT) posted its earnings results on Tuesday, March, 5th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.15.
How do I buy shares of Purple Biotech?: Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PPBT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial